Literature DB >> 11389161

GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.

K Muroya1, T Hasegawa, Y Ito, T Nagai, H Isotani, Y Iwata, K Yamamoto, S Fujimoto, S Seishu, Y Fukushima, Y Hasegawa, T Ogata.   

Abstract

We report on GATA3 analysis and the phenotypic spectrum in nine Japanese families with the HDR syndrome (hypoparathyroidism, sensorineural deafness, and renal dysplasia) (MIM 146255). Fluorescence in situ hybridisation and microsatellite analyses showed heterozygous gross deletions including GATA3 in four families. Sequence analysis showed heterozygous novel mutations in three families: a missense mutation within the first zinc finger domain at exon 4 (T823A, W275R), an unusual mutation at exon 4 (900insAA plus 901insCCT or C901AACCCT) resulting in a premature stop at codon 357 with loss of the second zinc finger domain, and a nonsense mutation at exon 6 (C1099T, R367X). No GATA3 abnormalities were identified in the remaining two families. The triad of HDR syndrome was variably manifested by patients with GATA3 abnormalities. The results suggest that HDR syndrome is primarily caused by GATA3 haploinsufficiency and is associated with a wide phenotypic spectrum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389161      PMCID: PMC1734904          DOI: 10.1136/jmg.38.6.374

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  43 in total

Review 1.  Genetic Disorders of Parathyroid Development and Function.

Authors:  Rebecca J Gordon; Michael A Levine
Journal:  Endocrinol Metab Clin North Am       Date:  2018-10-12       Impact factor: 4.741

2.  Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma.

Authors:  Nathan Young; Natallia Mikhalkevich; Ying Yan; Di Chen; Wei-ping Zheng
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

3.  A novel heterozygous deletion frameshift mutation of GATA3 in a Japanese kindred with the hypoparathyroidism, deafness and renal dysplasia syndrome.

Authors:  H Kobayashi; M Kasahara; M Hino; H Yoshimura; S Takahara; K Ikeda; C Son; T Iwakura; A Yoshimoto; T Ishihara; Y Ogawa
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

Review 4.  Role of the GATA family of transcription factors in endocrine development, function, and disease.

Authors:  Robert S Viger; Séverine Mazaud Guittot; Mikko Anttonen; David B Wilson; Markku Heikinheimo
Journal:  Mol Endocrinol       Date:  2008-01-03

5.  Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast.

Authors:  Adam M Deutschbauer; Daniel F Jaramillo; Michael Proctor; Jochen Kumm; Maureen E Hillenmeyer; Ronald W Davis; Corey Nislow; Guri Giaever
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

6.  Using mouse models to understand normal and abnormal urogenital tract development.

Authors:  Cathy Mendelsohn
Journal:  Organogenesis       Date:  2009-01       Impact factor: 2.500

7.  GATA3 mutation in a family with hypoparathyroidism, deafness and renal dysplasia syndrome.

Authors:  Zi-Yang Zhu; Qiao-Li Zhou; Shi-Ning Ni; Wei Gu
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

Review 8.  Vesicoureteric reflux and reflux nephropathy: from mouse models to childhood disease.

Authors:  Marie-Lyne Fillion; Christine L Watt; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2014-02-06       Impact factor: 3.714

9.  Dosage-dependent rescue of definitive nephrogenesis by a distant Gata3 enhancer.

Authors:  Susan L Hasegawa; Takashi Moriguchi; Arvind Rao; Takashi Kuroha; James Douglas Engel; Kim-Chew Lim
Journal:  Dev Biol       Date:  2006-09-22       Impact factor: 3.582

10.  GATA3 haploinsufficiency does not block allergic sensitization or atopic disease.

Authors:  Monica G Lawrence; Jennifer W Leiding; Jonathan J Lyons; Amy P Hsu; Celeste C Nelson; Nina Jones; Alan Fitzgerald; Wade W Chien; Lisa Workman; Thomas A Platts-Mills; Carmen Brewer; Rachel I Gafni; Kelly D Stone; Joshua D Milner; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2015-08-15       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.